Member Info for Terrier54

Yes this going to get very lucrative.
These boys are real deal.
GLE

YOP trading at €1.22 after touching $1.40. Nice.

Push over 100p this afternoon.
Natural pullback should soon be cleared.

Good breather to buy in. All decent trades are delayed so 120p range before long imo.

Warrants being sold. Fair enough when you have a two and half bagger.

The block sellers used the positive update to sell into.
Can only help to cleanse them and move on.

Price chart looks excellent.
Sit back and accumulate.

My mistake yep that's why the crew doesn't want it squeezed.

Citadel being shafted on Silver, nice.

This has more wind ups than a Cuckoo clock !

Excellent news.
Onwards and Upwards.

Esta
Hear what you say but I've seen so much in AIM companies over the years to know that all that glitters sometimes isn't gold.
Interesting though David Palumbo has been appointed as a Non-executive Director of PIRI today.

Multi-bagger for the Bod. Who wouldn't cash those in now ?

Excellent appointment, top operator.
Big things coming here.

Reducing again.
Hopefully this lot will clear off especially with the pressure being put on hedge funds in designated companies in the US.

If shorting was banned like it is some countries we wouldn't have these false movements.

When they opened this up 2% lower this morning after a decent finish and support yesterday you just know they are just playing games.
The whole process you be investigated and short selling banned like it is in some countries.

Yes the recent GameShop situation has highlighted how at a disadvantage the small investor is.
They just move it up in their own time and make more money.
Stinks.

Solid delayed buys showing.
Rise after the consolidation.

I would expect some update on this combination before too long.
Following successful completion of the Part A safety phase, the Part B cohort expansion phase of the trial is enrolling at multiple sites, and will assess the clinical benefit of the combination of MRx0518 and KEYTRUDA in addition to safety, in up to 30 additional patients per tumour type. The study is open-label and 4D pharma expects to make periodic announcements on progress and updated results as appropriate.

The trial is enrolling heavily pre-treated metastatic patients with selected solid tumours refractory to ICIs. Eligible patients must have experienced at least stable disease on previous ICI therapy (as a monotherapy or combination) but eventually progressed, as confirmed by two radiological scans =4 weeks apart in the absence of rapid clinical progression and within 12 weeks of last dose of ICI. Patients are treated with 1 capsule of MRx0518 twice daily and pembrolizumab every 3 weeks for up to 35 cycles (approximately 2 years) or until disease progression. Tumour response is assessed every 9 weeks per the RECIST 1.1 criteria. The primary objective of Part B is to evaluate safety of the combination. Secondary objectives were to evaluate efficacy via overall response rate (ORR), duration of response (DOR), disease control rate (DCR) and progression-free survival (PFS).